DNTH: net income -$50.2M. DNTH expands pipeline with DNTH212 in-license, Phase 3 EMERGE trial; raises, extends runway to 2030

Filed August 4, 2026 · Period ending June 30, 2026 · Compared to 10-Q Aug 7, 2025 · ~2 min read

Key Changes

• high

  Company raised ~$1B in capital (Sept 2025 $288M offering, March 2026 $719M offering, $59M ATM sales) and extended cash runway from H2 2027 to 2030, providing ~3.5 years of operating capital to fund multiple Phase 3 programs.

  MD&A: Financing Activities verify on EDGAR →
• high

  Initiated Phase 3 EMERGE trial in gMG (June 2026) following positive Phase 2 MaGic results; top-line data expected H2 2028. First registrational trial for claseprubart.

  MD&A: EMERGE Trial verify on EDGAR →
• high

  In-licensed DNTH212 from Leads Biolabs (Oct 2025) for up to $38M upfront/near-term milestones ($30M paid), plus up to $962M in development/regulatory/sales milestones. Phase 1 initiated in China Dec 2025, expanding pipeline into rheumatology indications.

  MD&A: DNTH212 License verify on EDGAR →